Skip to content
Screener

Syndax Pharmaceuticals SNDX EBITDA

EBITDA at other companies

Incyte logo
IncyteINCY
$724.37M+30.9%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
-$8.11M—
Kura Oncology logo
Kura OncologyKURA
-$78.46M-21.7%
AbbVie logo
AbbVieABBV
$5.93B+2.7%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.67M+30.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$126.15M-18.3%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.76B+58.9%
Enterprise value$1.98B+48.9%
P/S8.1×-6.1×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Calculated from Syndax Pharmaceuticals’s reported figures.

−$34.2Mebit+
$4.0MDepreciation Depletion & Amortization
=-$30.2M

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154

FAQ

What is Syndax Pharmaceuticals's EBITDA?
Syndax Pharmaceuticals (SNDX) reported EBITDA of -$30.2M in Q1 2026.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Syndax Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude